| Range: | 6.06-16.905 | Vol Avg: | 169621 | Last Div: | 0 | Changes: | 0.62 |
| Beta: | 2.46 | Cap: | 0.62B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Feb 10 2023 | Empoloyees: | 28 | ||
| CUSIP: | 603170101 | CIK: | 0001933414 | ISIN: | US6031701013 | Country: | US |
| CEO: | Mr. Jon Congleton | Website: | https://mineralystx.com | ||||
MLYS 12.49 Stock Price Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow